Moving toward individualized target-based therapies in acute myeloid leukemia-Reference-Cited by-同舟云学术

Moving toward individualized target-based therapies in acute myeloid leukemia

Published:2023-02 Issue:2 Volume:34 Page:141-151
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bazinet A.,Kantarjian H.M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference109 articles.

1. American Cancer Society. Cancer Facts & Figures 2022. Available at https://www.cancer.org/research/cancer-facts-statistics.html. Published 2022. Accessed July 10, 2022.

2. Acute myeloid leukemia;Dohner;N Engl J Med,2015

3. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia;Yates;Cancer Chemother Rep,1973

4. Etoposide in acute leukemia. Past experience and future perspectives;Ho;Cancer,1991

5. FLAG-Ida, an effective regimen for high risk AML;Keating,1998

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021;Biomarker Research;2024-09-11

2. Identification of immunity- and ferroptosis-related signature genes as potential design targets for mRNA vaccines in AML patients;Aging;2024-08-29

3. Significance of targeting DNMT3A mutations in AML;Annals of Hematology;2024-07-30

4. Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024?;Expert Review of Hematology;2024-07-21

5. Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI‐503 against MLL::AF9‐driven acute myeloid leukaemia;British Journal of Haematology;2024-06-15